



Psoriasis (US)

OVERVIEW

The Psoriasis (PsO) market continues to grow, driven by the increasing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with the recent introductions of Novartis' Cosentyx, Eli Lilly's Taltz, and Valeant's Siliq. Tracking the interplay of these treatments will be central to the 2017 report series, as well as assessing the impact of potential new market entrants, including Janssen's guselkumab, Boehringer Ingelheim/AbbVie's risankizumab, Merck/Sun Pharma's tildrakizumab, UCB's bimekizumab, and UCB's Cimzia will undoubtedly impact the ever-evolving psoriasis landscape.

The **RealTime Dynamix™: Psoriasis (US)** report series provides a detailed and timely look at current and future trends in the PsO market, and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the dermatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

SAMPLE & METHODOLOGY

The report is based on an online survey of ~100 US dermatologists and is fielded on a quarterly basis. Respondents are recruited from the Spherix Network, a proprietary group of dermatologists in clinical practice meeting quality screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output.

KEY QUESTIONS ANSWERED

- How will the entrance of Taltz and Siliq impact overall IL-17 class share vs. compete for share with Cosentyx?
- Will dermatologists overcome their struggle to differentiate Taltz from Cosentyx?
- What is the impact of the growing IL-17 class on Stelara and anti-TNF use?
- What is the profile of the growing Taltz patient population?
- What is the awareness of the pipeline agents in phase III and which of them are most anticipated to disrupt the current treatment approach?
- What uptake will there be of Siliq (brodalumab), in the face of warnings and restrictions in the approved label?
- How is Otezla holding ground against the increasingly competitive biologics?

Products Profiled

Commercial Products

AbbVie's Humira, Amgen's Enbrel, Celgene's Otezla, Eli Lilly's Taltz, Janssen's Remicade, Simponi & Stelara, Novartis' Cosentyx, UCB's Cimzia, Valeant's Siliq, Janssen's Tremfya, Merck's Renflexis

Pipeline Agents

BI/AbbVie's risankizumab, BMS' Orencia, Merck/Sun Pharma's tildrakizumab, UCB's bimekizumab

Key Dates

- Q1 March
- Q2 June
- Q3 September
- Q4 December

Note: a three day embargo is placed on delivery to non-manufacturers allowing clients time to digest the findings before public dissemination

Deliverables

- PowerPoint report
- Frequency Tables & Summary Statistics
- On-site presentation
- Proprietary questions (for purchasers of the annual series)

Related Reports 2017

- RealWorld Dynamix™: Biologic/Otezla Switching in Psoriasis US
- RealTime Dynamix™: Atopic Dermatitis US
- RealTime Dynamix™: Psoriatic Arthritis US
- RealTime Dynamix™: Psoriatic Arthritis EU
- RealWorld Dynamix™: Biologic/Otezla Switching in Psoriatic Arthritis US

Pricing

- \$19,500 single quarterly wave
- \$69,500 annual series of four reports